Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis.
Open Access
- 15 April 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 147 (5), 444-452
- https://doi.org/10.1093/ajcp/aqw222
Abstract
Objectives: To compare the mutational profiles of patients with primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocytosis (ET). Methods: Next-generation sequencing results of 75 cases of PMF, 33 cases of PV, and 27 cases of ET were compared. Results: Mutation rates of ASXL1 and SRSF2 were significantly higher in PMF than in PV or ET. ASXL1 mutations appeared to be more frequently associated with risk of transformation to acute myeloid leukemia than JAK2 or TET2 mutations. The most common mutation-cytogenetic combinations in myeloproliferative neoplasm (MPN) were mutations of JAK2 or ASXL1 with del(20q) and were more common in patients with PMF and PV than in patients with ET. Differences were also found between patients with PMF and PV. Conclusions: PMF, PV, and ET show different mutational profiles, which may be helpful in resolving the differential diagnosis between MPNs. Due to the relatively small number of cases and variable testing over time, larger controlled studies are necessary to confirm the findings.Keywords
This publication has 29 references indexed in Scilit:
- Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- Myeloproliferative NeoplasmsJAMA Oncology, 2015
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosisBlood, 2014
- Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617FThe Journal of Experimental Medicine, 2014
- Myelofibrotic Transformations of Polycythemia Vera and Essential Thrombocythemia are Morphologically, Biologically, and Prognostically Indistinguishable From Primary MyelofibrosisApplied Immunohistochemistry & Molecular Morphology, 2014
- Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutationsHaematologica, 2014
- Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemiaLeukemia, 2013
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in MyelofibrosisThe New England Journal of Medicine, 2010
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1Leukemia, 2010
- The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosisCurrent Hematologic Malignancy Reports, 2008